And the results in this study demonstrated reduced stroke volume and improved neuronal deficits after stroke intervened by CasRx-Ripk1-Nsf, which suggested that advances in CRISPR/CasRx-mediated multi-gene therapy are paving the way for future therapeutic applications in ischemic stroke. The gene discussed is NSF; the disease is Stroke.